KODIAK SCIENCES INC. Net Income (Loss) Available to Common Stockholders, Basic
KODIAK SCIENCES INC. (KOD) reported Net Income (Loss) Available to Common Stockholders, Basic of -$7.98 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-15.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2019-05-15
- KODIAK SCIENCES INC. net income (loss) available to common stockholders, basic for the quarter ending 2019-03-31 was -$7.98M.
- KODIAK SCIENCES INC. net income (loss) available to common stockholders, basic for the quarter ending 2018-12-31 was -$14.66M.
- KODIAK SCIENCES INC. net income (loss) available to common stockholders, basic for the quarter ending 2018-09-30 was -$10.45M.
- KODIAK SCIENCES INC. net income (loss) available to common stockholders, basic for the quarter ending 2018-03-31 was -$8.92M.
- KODIAK SCIENCES INC. net income (loss) available to common stockholders, basic for fiscal 2018 was -$41.44M.
- KODIAK SCIENCES INC. net income (loss) available to common stockholders, basic for fiscal 2017 was -$27.94M.
- KODIAK SCIENCES INC. net income (loss) available to common stockholders, basic for fiscal 2016 was -$17.13M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2019-03-31 | -$7.98M 10-Q · filed 2019-05-15 | -$22.65M derived: sum of 2 quarters · filed 2019-05-15 | -$33.10M derived: sum of 3 quarters · filed 2019-05-15 | |
| 2018-12-31 | -$14.66M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-27 | -$25.11M derived: sum of 2 quarters · filed 2019-03-27 | -$41.44M 10-K · filed 2019-03-27 | |
| 2018-09-30 | -$10.45M 10-Q · filed 2018-11-16 | -$26.78M 10-Q · filed 2018-11-16 | ||
| 2018-03-31 | -$8.92M 10-Q · filed 2019-05-15 | -$20.49M derived: sum of 2 quarters · filed 2019-05-15 | -$25.07M derived: sum of 3 quarters · filed 2019-05-15 | |
| 2017-12-31 | -$11.57M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-27 | -$16.15M derived: sum of 2 quarters · filed 2019-03-27 | -$27.94M 10-K · filed 2019-03-27 | |
| 2017-09-30 | -$4.58M 10-Q · filed 2018-11-16 | -$16.37M 10-Q · filed 2018-11-16 | ||
| 2016-12-31 | -$17.13M 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |